Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta

Executive Summary

Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working

You may also be interested in...



Trajenta’s German Renaissance Nipped In The Bud; Revised Dossier Falls Short

Comparator issues have wrecked reimbursement prospects for the second time for Boehringer/Lilly’s diabetes drug Trajenta in Germany as authorities dispute the utility of a study published in The Lancet comparing the product to the sulphonylurea glimepiride.

Boehringer Ingelheim Shrugs Off Patent Cliff, Returns To Sales Growth

Germany's Boehringer Ingelheim returns to sales growth and looks to Phase III hepatitis C and oncology products to provide long-term growth.

European Regulatory Round-Up: New Faces; Revised Guidances; More Cost Controls

A new chairman will take the helm of Germany's G-BA panel at a pivotal time for AMNOG implementation; the European Medicines Agency issues guidances in oncology drug development and genotoxicity; more regulatory updates.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel